We are live on ! Find out more
Nisa Investment Advisors

Nisa Investment Advisors Portfolio holdings

AUM $32B
1-Year Est. Return 32.86%
This Fund
S&P 500
This Quarter Est. Return
+7.2%
1 Year Est. Return
+32.86%
3 Year Est. Return
+108.44%
5 Year Est. Return
+138.89%
10 Year Est. Return
+505.54%
AUM
$16.9B
AUM Growth
+$992M
Cap. Flow
+$32.1M
Cap. Flow %
0.19%
Top 10 Hldgs %
29.79%
Holding
3,097
New
161
Increased
1,158
Reduced
1,190
Closed
136

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$107M
2
NVDA icon
NVIDIA
NVDA
+$43.5M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$41.6M
4
VZ icon
Verizon
VZ
+$37.4M
5
CSCO icon
Cisco
CSCO
+$27.8M

Sector Composition

Rank Sector Weight
1 Technology 29.39%
2 Financials 11.93%
3 Healthcare 11.32%
4 Communication Services 9.72%
5 Consumer Discretionary 9.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRCA icon
2901
Verrica Pharmaceuticals
VRCA
$90.9M
$109 ﹤0.01%
8
+5
+167% +$225
CCBG icon
2902
Capital City Bank Group
CCBG
$893M
$106 ﹤0.01%
3
-230
-99% -$7.55K
DIBS icon
2903
1stdibs.com
DIBS
$159M
$106 ﹤0.01%
24
SES icon
2904
SES AI
SES
$206M
$106 ﹤0.01%
165
+1
+0.6% +$1
DGICA icon
2905
Donegal Group Class A
DGICA
$694M
$103 ﹤0.01%
7
MGTX icon
2906
MeiraGTx Holdings
MGTX
$1.2B
$100 ﹤0.01%
24
-67
-74% -$290
MOND
2907
DELISTED
Mondee Holdings, Inc. Class A Common Stock
MOND
$99 ﹤0.01%
71
-7,146
-99% -$15.1K
MASS icon
2908
908 Devices
MASS
$393M
$97 ﹤0.01%
28
-4
-13% -$18
RCKY icon
2909
Rocky Brands
RCKY
$364M
$96 ﹤0.01%
3
-7
-70% -$222
CLAR icon
2910
Clarus
CLAR
$149M
$95 ﹤0.01%
21
-85
-80% -$428
JSPR icon
2911
Jasper Therapeutics
JSPR
$29.5M
$94 ﹤0.01%
+5
New +$100
PRPL icon
2912
Purple Innovation
PRPL
$30.5M
$94 ﹤0.01%
4
+3
+300% +$87
EVCM icon
2913
EverCommerce
EVCM
$1.78B
$93 ﹤0.01%
9
-60
-87% -$648
ELEV
2914
DELISTED
Elevation Oncology
ELEV
$88 ﹤0.01%
+147
New +$218
TMCI icon
2915
Treace Medical Concepts
TMCI
$304M
$87 ﹤0.01%
15
-9,257
-100% -$59.5K
STXS icon
2916
Stereotaxis
STXS
$144M
$86 ﹤0.01%
+42
New +$85
HBIO icon
2917
Harvard Bioscience
HBIO
$28.1M
$83 ﹤0.01%
3
-10
-77% -$295
EHTH icon
2918
eHealth
EHTH
$40M
$82 ﹤0.01%
20
OTLK icon
2919
Outlook Therapeutics
OTLK
$208M
$80 ﹤0.01%
15
-2,303
-99% -$16.9K
ANRO icon
2920
Alto Neuroscience
ANRO
$1.08B
$80 ﹤0.01%
+7
New +$86
SKIL icon
2921
Skillsoft
SKIL
$88.6M
$78 ﹤0.01%
5
-30
-86% -$427
TIPT icon
2922
Tiptree Inc
TIPT
$673M
$78 ﹤0.01%
4
NVCT icon
2923
Nuvectis Pharma
NVCT
$618M
$75 ﹤0.01%
12
-200
-94% -$1.32K
PDSB icon
2924
PDS Biotechnology
PDSB
$19.2M
$69 ﹤0.01%
18
-35
-66% -$117
KRMD icon
2925
KORU Medical Systems
KRMD
$159M
$68 ﹤0.01%
25
-50
-67% -$123

Similar funds

Nisa Investment Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Nisa Investment Advisors held 3,097 positions worth $16.9B, up 6.2% from $15.9B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Nisa Investment Advisors's Q3 2024 filing shows 161 new, 1,158 increased, 1,190 reduced and 136 closed positions. Its largest new stake was Schwab Short-Term US Treasury ETF: 580,000 shares worth $14.2M. The largest sale was iShares MSCI Emerging Markets ETF, an estimated $74.5M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 30% a quarter earlier, followed by Financials and Healthcare.

  • Nisa Investment Advisors's largest Q3 2024 buy was Schwab Short-Term US Treasury ETF: 580,000 shares worth $14.2M.
  • Nisa Investment Advisors added most to Meta Platforms (Facebook) in Q3 2024, an estimated $107M increase.
  • Nisa Investment Advisors's biggest Q3 2024 reduction was Apple, cutting an estimated $44.6M.
  • Nisa Investment Advisors fully exited iShares MSCI Emerging Markets ETF in Q3 2024, selling an estimated $74.5M.
  • Nisa Investment Advisors's ten largest holdings make up 30% of its $16.9B portfolio in Q3 2024.
  • Nisa Investment Advisors opened 161 new positions and closed 136 in Q3 2024.
  • Nisa Investment Advisors's portfolio value rose 6.2% quarter-over-quarter to $16.9B.

Based on Nisa Investment Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.